Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05753722 · ClinicalTrials.gov registry record · Phase 1

A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

A Phase 1 study of Non-Small Cell Lung Cancer and NSCLC, sponsored by Incendia Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
270
Enrollment target
11
Study locations

NCT05753722 is a Phase 1 study of Non-Small Cell Lung Cancer and NSCLC that is actively recruiting participants, run by Incendia Therapeutics. The registered enrollment target is 270 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (59% lower). The trial reports 11 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05753722, a Phase 1 study of Non-Small Cell Lung Cancer and NSCLC, is actively recruiting participants, sponsored by Incendia Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
270 participants
Enrollment target
11
Study locations

Study Summary

The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101 alone or in combination with pembrolizumab in adults with advance or metastatic solid tumors.

Conditions Studied

Non-Small Cell Lung Cancer NSCLC Advanced or Metastatic Solid Tumors

Interventions

  • BIOLOGICAL Pembrolizumab
  • BIOLOGICAL PRTH-101

Study Locations (11)

Texas

  • The University of Texas MD Anderson Cancer Center - Houston
  • NEXT Houston - Houston
  • Next Oncology - Irving
  • NEXT Oncology - San Antonio

Arizona

  • Honor Health Research Institute - Scottsdale

Connecticut

  • Yale Cancer Center - New Haven

Massachusetts

  • Mass General Cancer Center - Boston

Oregon

  • Providence Cancer Institute Franz Clinic - Portland

Pennsylvania

  • University of Pittsburgh Medical Center Hillman Cancer Center - Pittsburgh

Tennessee

  • Vanderbilt-Ingram Cancer Center - Nashville

Virginia

  • Next Oncology - Fairfax

Trial Details

FieldValue
Enrollment Target 270 participants
Start Date 2023-03-03
Est. Completion 2027-09-30
Phase Phase 1

Sponsor

Incendia Therapeutics

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05753722

The ClinicalTrials.gov registry entry for NCT05753722 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 270 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (59% lower). The listed sponsor is Incendia Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT05753722 reports 11 study locations spanning 8 distinct geographic areas - top geographies include Texas, Arizona, Connecticut.

Frequently Asked Questions

What is clinical trial NCT05753722 about?

NCT05753722 is a clinical study titled "A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies". The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101 alone or in combination with pembrolizumab in adults with advance or metastatic solid tumors.

What is the current status of trial NCT05753722?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 270 participants. The study started on 2023-03-03. Estimated completion is 2027-09-30.

What conditions does trial NCT05753722 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, NSCLC, Advanced or Metastatic Solid Tumors.

What interventions are being tested in trial NCT05753722?

The interventions under investigation include: Pembrolizumab (BIOLOGICAL), PRTH-101 (BIOLOGICAL).

Who is sponsoring clinical trial NCT05753722?

This trial is sponsored by Incendia Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05753722 being conducted?

This trial has 11 study locations across Arizona, Connecticut, Massachusetts, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Small Cell Lung Cancer

All registered trials for this condition

NSCLC

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.